PTEN and neoplasm: Despite the persistence of this positive predictive biomarker along with MSI, and the lack of aberrations in resistance genes (Janus kinase 2 [JAK2], phosphatase and tensin homolog [PTEN], serine/threonine kinase 11 [STK11]), the patient ended up with tumor progression on immunotherapy.